跳至主要内容
临床试验/NL-OMON20649
NL-OMON20649尚未招募不适用

Pharmacokinetics of- and interaction between aprepitant and dexamethasone

Princess Maxima Center for pediatric oncology0 个研究点目标入组 20 人开始时间: 待定最近更新:

试验速览

阶段
不适用
状态
尚未招募
发起方
入组人数
20

研究概览

简要总结

暂无简介。

研究设计

研究类型
Observational

入排标准

入选标准

  • 1.Planned to receive chemotherapy intravenously as regular treatment (standard of care);
  • 2.Receiving dexamethasone with or without aprepitant as standard of care
  • 3.Receiving the chemotherapy and anti-emetics during hospitalized treatment.
  • 4.Age =18;
  • 5.Signed Informed consent form (ICF) prior to participation in the study;
  • 6.Able and willing to undergo blood draw for the study (two different days, 6 times per day) and does not have any condition that makes participation disadvantageous;
  • 7.For women: not pregnant
  • 8.No use of strong CYP3A4 substrates or inhibitors within 7 days or CYP3A4 inducers within 30 days of treatment;

排除标准

  • See inclusion criteria

研究者

发起方
Princess Maxima Center for pediatric oncology

相似试验